OP-2100

N/A

Report date: 2026/05/11 20:01:57
NME

Base Information

Drug NameOP-2100
Drug Alias NameOP-2100
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitors
TargetsDNA (cytosine-5)-methyltransferase 1
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A